Inventor · disambiguated record
Pedro Beltran
Also filed as: BELTRAN PEDRO · BELTRAN PEDRO J
2 granted patents·9 pending applications·1 citations·filing 2008–2023
32Inventor score
Top patents by PatentIndex Score
11 records- 0159US8961970B2Combination therapyHUANG XIZHONG·Filed 2013·Granted Feb 24, 2015·1 cites·10 claims
- 0257US2025268900A1Combination therapy using a substituted pyrimidin-4(3h)-one and nivolumab as well as its use in the treatment of cancerBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 0354US2025195520A1Combination therapy using a ptpn11 inhibitor and an egfr inhibitorNAVIRE PHARMA INC·Filed 2022·Application pending·0 cites
- 0454US2025230138A1Compounds having a t-structure formed by at least four cycles for use in the treatment of cancer and other indicationsTHERAS INC·Filed 2023·Application pending·0 cites
- 0553US2025009748A1Combination therapy using substituted pyrimidin-4(3h)-ones and sotorasibNAVIRE PHARMA INC·Filed 2022·Application pending·0 cites
- 0651US2025213563A1Substituted pyrimidin-4(3h)-ones for use in treating cancerNAVIRE PHARMA INC·Filed 2022·Application pending·0 cites
- 0749US11078288B2Methods and compositions for treating tumor diseasesAMGEN INC·Filed 2018·Granted Aug 3, 2021·0 cites·20 claims
- 0845US2010166747A1Methods and compositions for treating tumor diseasesBELTRAN PEDRO J·Filed 2008·Application pending·0 cites
- 0942US2021379078A1Killing Senescent Cells And Treating Senescence-Associated Conditions Using A Bcl Inhibitor And An Mcl-1 InhibitorUNITY BIOTECHNOLOGY INC·Filed 2019·Application pending·0 cites
- 1036US2020009204A1Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancerAMGEN INC·Filed 2018·Application pending·0 cites
- 1133US2021332141A1Insulin-like growth factor-1 receptor (igf-1r) binding proteins and methods of useCOHEN PINCHAS·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Pedro Beltran files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →